Testing blood-clot guidance for ICU patients with severe lung failure
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial tests whether using a blood test that shows clotting strength and “clot breakdown time” can help guide treatment for people in the ICU with acute respiratory failure from infection. If you qualify, the team will use these blood results to decide on clot-related therapy and compare outcomes to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Be admitted to the ICU for sudden, severe breathing failure from an infection in the lungs or elsewhere
- Have low oxygen levels despite support (oxygen level ratio fits the study’s cutoff) and use PEEP 5 or higher
- Your blood test results must show a stronger tendency to clot plus enough time for clot breakdown (specific lab cutoffs)
- You must be able to have the study blood tests and receive active ICU treatment; the team believes you can survive at least the next day
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well the body's natural clot-busting system works in people with serious infections or major injuries. It may help doctors find better ways to treat these conditions.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
This trial tests whether a standard procedure using a catheter to deliver clot-dissolving medicine directly into the lung artery works well for people with a serious but not immediately life-threatening blood clot in the lungs (pulmonary embolism). It aims to improve heart function and reduce long-term complications.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This trial tests whether a clot-busting drug given directly into the brain artery can improve recovery after a major stroke caused by a blockage in the front part of the brain. The study is for people whose blood flow has already been successfully restored with standard treatments.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
Hear when a new Acute Respiratory Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.